| abstract |
A method for monitoring the development of acute respiratory distress syndrome (ARDS) in a patient, wherein: 1) serum samples are obtained from the patient at different points of time, 2) said serum samples are tested by chemical analysis for determining 3 - 8 of ARDS-related biomarkers, and wherein at least two of the biomarkers are CD73 protein and IL-6 and other biomarkers are selected from the group consisting of IL-8, IL-15, Eotaxin, MPC-1, MIP-la and IL-lra. The method is based on comparing the levels or activities of the biomarkers obtained in a first serum sample obtained at a later point of time to the levels or activities of the same biomarkers in a second serum sample obtained at a previous point of time, wherein an increase in the level or activity of CD73, Eotaxin and/or MIP-la and/or a decrease in the level or activity of IL-6, IL-8, IL-15, IL-lra and/or MPC-1 represent a regression of ARDS, and wherein a decrease in the level or activity of CD73 and/or an increase in the level or activity of IL-6, IL-8, IL-15, IL-lra and MPC-1, represents a worsening of ARDS. |